A domestic biosimilar taking an unstoppable run in the global market
The Celltrion’s rheumatoid arthritis treatment, ‘Remsima,’ has continued to accelerate in the global market. The number of exports from the early year to June has already exceeded the one of the last whole year.
Remsima is the world’s first antibody biosimilar developed by Celltrion having the J...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
